We parkies just love good news

[Xenos]

This one is about Nilotinib (AKA Tasigna) and not really new, but I don't care, since it's good news...

parkinsonsnewstoday.com/201...

[bassofspades]

Glad to see this!

[WinnieThePoo]

It's a phase 2 human trial

[reedboat2 in reply to WinnieThePoo]

Tasigna already approved for Leukemia so that makes sense

[Xenos in reply to reedboat2]

Makes sense... and potentially reduce the whole process of approval to something like a year (?).

[park_bear in reply to Xenos]

No unfortunately. What was published was a pharmacodynamics study undertaken as part of an ongoing phase 2 study which will take some months to complete. After that a large expensive randomized controlled double-blind phase 3 study is usually needed. Expect that to take several years to complete.

[PDGal4]

"Taken together, 200 mg Nilotinib appears to be an optimal single dose that concurrently reduces inflammation and engages surrogate disease biomarkers, including dopamine metabolism and alpha‐synuclein,” researchers stated.

Note that. "single dose" has to be repeated daily. When treatment stops, alpha-synuclein returns and so do symptoms.